Letermovir prophylaxis for cytomegalovirus and immune reconstitution after allogeneic hematopoietic stem cell transplantation: A single-center real-world study (ASH 2025) - Nov 4, 2025 - Abstract #abs25-15018; 6063; Pres time: Dec 8, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Letermovir reduces the incidence of csCMVi after allo-HSCT, but it increases the risk ofEBV/PTLD, which may be related to the influence of lymphocyte reconstitution."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation
|
|
Xueyao Li1,2; Yigeng Cao1,2; Wenhao Wang1,2,3; Erlie Jiang1,2
|